...- Bioplan USA Inc. amended and extended the maturity of its term loans, reducing near-term liquidity and refinancing risks. The company also received an equity injection of $20 million from its sponsor, Oaktree Capital, that improves its liquidity position. - S&P Global Ratings still expects the company to face secular pressures driven by retail store closures, and remain vulnerable to marketing spend decisions of its client base. - We raised our issuer credit rating on the company to '###+' from '###'. - We raised our rating on the company's first-lien term loan facility to '###+' from '###'. We also raised our rating on the company's second-lien term loan facility to '###' from '###-'. - The negative outlook reflects our expectations that there will continue to be secular pressures in physical retail stores, which could limit Bioplan's upside post-COVID, and that weaker-than-expected operating performance could accelerate the company's cash burn....
